ERBB2 and breast cancer: Although the development of hormone and HER2-targeted therapies has greatly improved the prognosis of patients with luminal A/B and HER2 breast cancer, respectively, the emergence of resistance remains a major problem, limiting the effectiveness of drug treatment.